Recently, Medicilon has officially obtained the Good Laboratory Practice (GLP)  certificate issued by Mexico, a member country of the Organization for Economic Co-operation and Development (OECD). Medicilon also has passed the GLP on-site inspections conducted by Hungary, another member country of the OECD. Following the recent FDA and PMDA GLP audit , this success further affirms that Medicilon’s preclinical research quality meets the highest international standard.

Committed to Compliance Management System, Empowering Global Drug Innovation

OECD GLP certificate is widely regarded as the gold standard in international preclinical safety evaluation for its rigor, comprehensiveness, and sustainability. Medicilon operates under a “one-system, multi-country recognition” framework, aligning its laboratory operations and management with GLP requirements from regulatory bodies such as China’s NMPA, the U.S. FDA, Australia’s TGA, Europe’s EMA, South Korea’s MFDS. Building on NMPA, ICH, and FDA standards, Medicilon has established an advanced preclinical research platform supporting innovative therapies including ADCs, PROTACs, antibodies, and nucleic acid drugs.

Medicilon remains dedicated to collaborating with clients worldwide through its integrated preclinical R&D service platform, helping to overcome technical barriers and advancing the development of innovative medicine.